INO · Inovio Pharmaceuticals, Inc. · Exempt Offerings
$1.13
-0.02 (-1.74%)
At close · Oct 6
View the 10-K filed Mar 12, 2026
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Customer concentration
— key customers 100% of revenue
Key customers — 100% of revenue (the years ended December 31, 2025 and 2024)
“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
Market Cap
$122.01M
Shares
103.40M
Volume · Oct 6
2.01M
Avg daily vol (3M)
3.77M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.